Contract Services

CIDP to unveil new study protocol at in-cosmetics Global 2018

CIDP, Centre International de Développement Pharmaceutique, a private and independent Contract Research Organisation (CRO), today announces its participation in In-Cosmetics Global 2018 from 17 – 19 April in Amsterdam. After successfully setting up its Unique Pollution Exposure System in 2017, for the standardization of the anti-pollution claim and having developed an ex vivo model, CIDP continues its innovative endeavour by offering the possibility of skin microbiome evaluation.

Skin Microbiota
It is now well established within the scientific communities that a well-balanced microbiota is essential for a healthy and beautiful skin. Just like the human gut, the skin contains a variety of microbial communities comprising of bacteria, fungi, yeast and viruses. Some of these are considered beneficial while others are considered harmful to the skin. However, it is important to have a good biodiversity and an evenness in the microbe’s distribution to maintain a healthy skin.

Cosmetics products can help to maintain the skin healthy by:

  1. Maintaining a healthy well-balanced microbiome
  2. Having a Probiotic effect: improves the microbiota by the addition of living “good” bacteria or extracts from living bacteria
  3. Having a Prebiotic effect: actives which will rebalance the microbiota.

Many cosmetic brands have understood the opportunities that exist due to the connection between a healthy, beautiful skin and a balanced microbiome. Various cosmetics products have already been commercialised.

As an innovative CRO, CIDP is providing innovative solution to substantiate these claims. They are indeed providing study protocols that allow evaluation of skin microbiome by new methods such as 16S-rRNA Gene Sequencing, whereby bacteria can be identified to their specific genes.

On 17 April at 11:20am, Mrs Véronique NEWTON, R&D Laboratory Manager at CIDP, will present the company’s standard protocols for objective substantiation of anti-pollution claims. She will also share more about CIDP’s successful creation of an ex vivo model that mimics in vivo conditions.

Visitors can also find out more about CIDP’s study protocol and full suite of services – which comprises research activities, in vitro testing, analytical chemistry, formulation, and clinical research – at Booth H150.

For more information, please visit